Rigel Pharmaceutical Inc. buy tamam
Start price
18.04.17
/
50%
€2.93
Target price
22.05.17
€3.61
Performance (%)
-21.85%
End price
22.05.17
€2.29
Summary
This prediction ended on 22.05.17 with a price of €2.29. The prediction for Rigel Pharmaceutical Inc. disappointed with a performance of -21.85%. tamam has 50% into this predictionPerformance without dividends (%)
| Name | 1w | 1m | 1y | 3y |
|---|---|---|---|---|
| Rigel Pharmaceutical Inc. | - | - | - | - |
| iShares Core DAX® | -0.528% | 3.111% | 3.876% | 53.900% |
| iShares Nasdaq 100 | 2.160% | 12.690% | 40.737% | 95.909% |
| iShares Nikkei 225® | 2.417% | 11.540% | 57.544% | 69.134% |
| iShares S&P 500 | 1.206% | 6.564% | 27.347% | 69.098% |
Comments by tamam for this prediction
In the thread Rigel Pharmaceutical Inc. diskutieren
Rigel Pharmaceuticals (NASDAQ:RIGL) submits a New Drug Application
- to the FDA seeking approval of fostamatinib for the treatment of
patients with chronic and persistent immune thrombocytopenia (ITP), an Orphan Drug indication.
- Fostamatinib inhibits an enzyme called spleen tyrosine kinase (SYK) which plays a key role in certain blood cancers and autoimmune disorders.
(Vom Mitglied beendet)